NHWD-870（Cat No.:I045298）is a potent, selective small-molecule inhibitor of the bromodomain and extra-terminal (BET) family proteins, which regulate gene expression by binding acetylated histones. By disrupting BET–chromatin interactions, NHWD-870 downregulates oncogenic transcription programs, including MYC-driven pathways, leading to inhibited tumor cell proliferation and survival. Preclinical studies have shown strong antitumor activity across multiple cancer models, including hematologic malignancies and solid tumors. Its high selectivity and favorable pharmacokinetic properties make NHWD-870 a promising candidate for targeted epigenetic therapy, offering potential for combination strategies to enhance efficacy and overcome drug resistance in cancer treatment.